Context: The mitral valve conducts blood flow from the left atrium to the left ventricle. Mitral regurgitation occurs when the valve

couldn’t be closed properly at the end of ventricular filling. Mitraclip, a catheter-based device that can reduce mitral regurgitation

without requiring open surgery, is routinely used for patients with unacceptable risk of conventional mitral valve repair or replacement.

Thepurpose of this study is assessing the safety, efficacy, andeconomicaspects of Mitraclip treatment for mitral regurgitation.

EvidenceAcquisition: TheCochrane Library, theTRIP database, andGoogle Scholar havebeensearchedthroughappropriate strategies.

Seven studies were included in the final phase based on the inclusion and exclusion criteria. Data collected from these studies

were analyzed based on four main themes; applications, safety, efficacy, and economic evaluation.

Results: The most potential side effects were related to an improper transfer of catheters and low durability of the device. One of

the included studies showed that improved outcomes of the New York Heart Association (NYHA) was more in the clip group with

better quality of life that were observed after 1 to 12 months in 192 patients and also one-year mortality rate after using clip ranged

between 10% and 24%. This included study found that 72% to 100% of patients with Mitraclip have been successfully treated and the

duration of hospital stays in these patients was between 5 to 10 days. The cost-effectiveness of the procedure still needs more robust


Conclusions: Giventhe lack of high quality evidenceand relatively high cost of Mitraclip, it seems that until further robustevidence

is produced; it should be used in research and in high risk patients selected after detailed examination with strict indications and

appropriate opinions of cardiologists.

<embed src="http://www.test.com/example.pdf" width="500" height="375">



No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *